Key result
Systemic administration of a muscle-specific AAV vector expressing HEV ORF3 induced robust, dose-dependent formation of anti-ORF3 antibodies in mice that moderately neutralized quasi-enveloped HEV.
Why the study?
Quasi-enveloped HEV particles are protected from neutralising anti-capsid antibodies, but most vaccine approaches target the HEV capsid rather than the quasi-enveloped form.
Does systemic administration of AAVMYO3 expressing ORF3 induce anti-ORF3 antibodies and inhibit quasi-enveloped HEV infection in mice?
Does systemic administration of AAVMYO3 expressing ORF3 induce anti-ORF3 antibodies and inhibit quasi-enveloped HEV infection in mice?
A novel AAVMYO3 vector expressing HEV ORF3 induces anti-ORF3 antibodies in mice, offering a potential vector-based vaccine platform against quasi-enveloped HEV.
The hepatitis E virus (HEV) is a major global health problem, leading to large outbreaks in the developing world and chronic infections in the developed world. HEV is a non-enveloped virus, which circulates in the blood in a quasi-enveloped form. The quasi-envelope protects HEV particles from neutralising anti-capsid antibodies in the serum; however, most vaccine approaches are designed to induce an immune response against the HEV capsid. In this study, we explored systemic in vivo administration of a novel synthetic and myotropic Adeno-associated virus vector (AAVMYO3) to express the small HEV phosphoprotein ORF3 (found on quasi-enveloped HEV) in the musculature of mice, resulting in the robust and dose-dependent formation of anti-ORF3 antibodies. Neutralisation assays using the serum of ORF3 AAV-transduced mice showed a modest inhibitory effect on the infection of quasi-enveloped HEV in vivo, comparable to previously characterised anti-ORF3 antibodies used as a control. The novel AAVMYO3 capsid used in this study can serve as a versatile platform for the continued development of vector-based vaccines against HEV and other infectious agents, which could complement traditional vaccines akin to the current positive experience with SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2022) studied Hepatitis E Virus (HEV) infection (n=12). AAVMYO3 vector expressing HEV ORF3 vs. AAVMYO3 vector expressing YFP was evaluated on Induction of anti-ORF3 antibodies and neutralisation of eHEV particles. Systemic administration of a muscle-specific AAV vector expressing HEV ORF3 induced robust, dose-dependent formation of anti-ORF3 antibodies in mice that moderately neutralized quasi-enveloped HEV.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: